Tesamorelin is the outlier on this site: a stabilised GHRH analogue that is an approved prescription medicine, licensed as Egrifta SV at 1.4 mg once daily and Egrifta WR at 1.28 mg once daily for HIV-associated lipodystrophy. The two formulations are not substitutable. Those are approved doses for a licensed indication, not research community conventions. You will still see an older 2 mg figure circulating; it belongs to the original Egrifta formulation, discontinued around 2020, and quoting it today is quoting a product that no longer exists. Research-grade tesamorelin ships as a 10 mg freeze-dried vial and must be reconstituted in bacteriostatic water. The table below shows each water volume's concentration, and the calculator converts amounts into syringe marks.
Open the Tesamorelin calculator →| Concentration | 1 mL water | 2 mL water | 3 mL water | 5 mL water |
|---|---|---|---|---|
| 10 mg vial | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL | 2,000 mcg/mL |
Concentration = vial contents ÷ water added. It is the same compound at every volume — more water only means a weaker solution, larger syringe marks that are easier to read, and a larger injection volume. On a standard U-100 insulin syringe, one unit is 0.01 mL at any barrel size.
Calculate a Tesamorelin draw →Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.
Arithmetic, not advice. The calculator performs unit-conversion arithmetic on figures you enter. It does not recommend a dose, a quantity, or a method of administration.
Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.
Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any protocol.